DECISION DOMAIN | SUMMARY OF REASON FOR DECISION | SUBDOMAINS INFLUENCING DECISION |
---|---|---|
QoE: Is there high- or moderate-quality evidence? Yes □ No ☑ | The QoE for the benefits of deprescribing is low to moderate The QoE for the harms of deprescribing is low to moderate | Key reason for downgrading is risk of bias The QoE from RCTs for benefits of deprescribing is low The QoE from RCTs for harms of deprescribing is moderate (sleep quality) |
Balance of benefits and harms: Is there certainty that the benefits outweigh the harms? Yes ☑ No □ | Effects of interventions on cessation rate
Sleep quality outcomes
Anxiety
Other harms of deprescribing (eg, adverse drug withdrawal effects)
Effect of deprescribing on cognition
Adverse events for the elderly
| Is the baseline risk of benefit of deprescribing similar across subgroups? Yes ☑ No □
Should there be separate recommendations for subgroups based on risk levels? Yes □ No ☑
Yes ☑ No □
Should there be separate recommendations for subgroups based on harms of continued use? Yes ☑ No □
|
Values and preferences: Is there confidence in the estimate of relative importance of outcomes and patient preferences? Yes □ No ☑ | Patients tend to rate the benefits of BZDs higher than physicians do and rate the risks lower. Those patients interested in stopping BZDs see potential improvements in thinking and memory as benefits, as well as obtaining more natural sleep and feeling proud of themselves for having stopped. Factors associated with increased likelihood of stopping BZRA use include higher education level, lower intake or potency of BZDs, and lower anxiety sensitivity scores. Of those who fail BZD discontinuation, many describe having experienced such failure as difficulty in sleeping within a few days of stopping | Perspective taken: Evidence suggests there are patients who wish to discontinue BZRAs to avoid the harms of long-term use. There are others who might be hesitant and might fail owing to difficulty sleeping after stopping Source of values and preferences: Scoping review on subjects including the elderly Source of variability, if any: Education levels, potency of BZRA, and anxiety sensitivity scores Method for determining values satisfactory for this recommendation? Yes ☑ No □ All critical outcomes measured? Yes ☑ No □ |
Resource implications: Are the resources worth the expected net benefit? Yes ☑ No □ | Cost implications
| Feasibility: Is tapering BZRA intervention generally available? Yes ☑ No □
Opportunity cost: Is this intervention and its effects worth withdrawing or not allocating resources from other interventions? Yes ☑ No □ Economic and preventive benefits for harms: Is there a lot of variability in resource requirements across settings? Yes □ No ☑
|
Overall strength of recommendation in older persons (≥ 65 y): strong Overall strength of recommendation in adults < 65 y: weak | There is low-quality evidence that deprescribing interventions improve cessation rates of BZRAs at 3 mo. Compared with continuation of BZRAs, tapering these drugs does not result in any difference in withdrawal symptom scores (low-quality evidence). Those who taper BZRAs might have more problems sleeping than those who continue; however, there is no difference at 12 mo (very low-quality evidence). Our systematic review found that deprescribing of BZRAs did not worsen anxiety. Despite low-quality evidence surrounding deprescribing, our recommendation was rated as strong in older persons owing to evidence surrounding harms of continued BZRA use specifically in older persons (associated increased risk of falls, cognitive impairment, motor vehicle accidents) and resultant resource implications. We also considered literature on patient preferences suggesting patients might value regaining control over sleep and potentially avoiding adverse effects of BZRAs |
BWSQ—benzodiazepine withdrawal symptom questionnaire, BZD—benzodiazepine, BZRA—benzodiazepine receptor agonist, CBT—cognitive-behavioural therapy, COPD—chronic obstructive pulmonary disease, NNT—number needed to treat, QoE—quality of evidence, RCT—randomized controlled trial.